Epstein–Barr nuclear antigen 1 (EBNA1)

Epstein–Barr nuclear antigen 1 (EBNA1) is a multifunctional dimeric protein encoded by the Epstein–Barr virus (EBV). It is essential for establishing and maintaining lifelong latent infection within human hosts. EBNA1 binds sequence-specifically to origin-of-replication elements on the viral episome—most notably oriP—to mediate replication and faithful segregation during cell division. It regulates both positive and negative aspects of viral gene expression through direct promoter interactions. Structurally unique among herpesvirus proteins, EBNA1 contains a glycine-alanine repeat that stabilizes it against proteasomal degradation while impairing MHC class I-mediated antigen presentation—a key mechanism allowing infected cells to evade cytotoxic T lymphocyte responses. Functionally analogous in part to cellular high mobility group A proteins (HMGA), EBNA1 can remodel host chromatin structure by decondensing heterochromatin regions via an arginine-glycine-rich domain similar to AT-hooks found in HMGAs; this activity globally alters cellular transcription profiles during infection. In addition to supporting persistent latency through genome maintenance functions—including tethering episomes via chromosome attachment domains—EBNA1 disrupts PML nuclear bodies involved in tumor suppression/DNA repair pathways, induces genomic instability, interacts with multiple cellular factors such as ribosomal protein L4, nucleolin, BRD4, CTCF, NAP family members, origin recognition complex components, thereby contributing directly or indirectly both to oncogenesis and long-term persistence. Because it is expressed universally across all forms/stages/types of latent infection—and uniquely so among viral antigens—it represents an attractive but challenging therapeutic target for intervention against all major forms of Epstein-Barr virus-associated disease.

Other names

EBV nuclear antigen 1EBV NA1Epstein–Barr virus nuclear antigen 1

Experimental inhibitors act by blocking the binding of EBNA1 to its cognate sites on viral DNA (oriP), disrupting maintenance/replication functions; some compounds compete for binding at these sequences or directly interact with functional domains critical for dimerization or chromatin tethering.